IART Fundamental Analysis - INTEGRA LIFESCIENCES HOLDING

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to IART. IART was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While IART is still in line with the averages on profitability rating, there are concerns on its financial health. IART has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IART was profitable.

IART had a positive operating cash flow in the past year.

IART had positive earnings in 4 of the past 5 years.

Each year in the past 5 years IART had a positive operating cash flow.

1.2 Ratios

With a decent Return On Assets value of -0.71%, IART is doing good in the industry, outperforming 71.66% of the companies in the same industry.

The Return On Equity of IART (-1.90%) is better than 72.19% of its industry peers.

IART has a better Return On Invested Capital (4.48%) than 76.47% of its industry peers.

IART had an Average Return On Invested Capital over the past 3 years of 6.10%. This is in line with the industry average of 7.89%.

		Industry Rank	Sector Rank
ROA	-0.71%
ROE	-1.9%
ROIC	4.48%

ROA(3y)2.09%

ROA(5y)2.89%

ROE(3y)4.61%

ROE(5y)6.54%

ROIC(3y)6.1%

ROIC(5y)6.15%

1.3 Margins

IART has a better Operating Margin (10.34%) than 77.54% of its industry peers.

IART's Operating Margin has declined in the last couple of years.

IART has a Gross Margin of 58.47%. This is comparable to the rest of the industry: IART outperforms 56.68% of its industry peers.

In the last couple of years the Gross Margin of IART has declined.

		Industry Rank	Sector Rank
OM	10.34%
PM (TTM)	N/A
GM	58.47%

OM growth 3Y-14.31%

OM growth 5Y-7.91%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.19%

GM growth 5Y-1.66%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IART is destroying value.

The number of shares outstanding for IART has been reduced compared to 1 year ago.

Compared to 5 years ago, IART has less shares outstanding

The debt/assets ratio for IART is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 1.16, we must say that IART is in the distress zone and has some risk of bankruptcy.

IART has a Altman-Z score of 1.16. This is comparable to the rest of the industry: IART outperforms 51.34% of its industry peers.

A Debt/Equity ratio of 0.81 indicates that IART is somewhat dependend on debt financing.

IART has a worse Debt to Equity ratio (0.81) than 74.87% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.81
Debt/FCF	N/A
Altman-Z	1.16

ROIC/WACC0.61

WACC7.4%

2.3 Liquidity

A Current Ratio of 1.21 indicates that IART should not have too much problems paying its short term obligations.

IART has a Current ratio of 1.21. This is amonst the worse of the industry: IART underperforms 82.89% of its industry peers.

A Quick Ratio of 0.72 indicates that IART may have some problems paying its short term obligations.

IART has a Quick ratio of 0.72. This is amonst the worse of the industry: IART underperforms 89.84% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.21
Quick Ratio	0.72

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.84%.

Measured over the past years, IART shows a decrease in Earnings Per Share. The EPS has been decreasing by -1.35% on average per year.

The Revenue has been growing slightly by 6.19% in the past year.

IART shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.20% yearly.

EPS 1Y (TTM)-16.84%

EPS 3Y-6.97%

EPS 5Y-1.35%

EPS Q2Q%-25.45%

Revenue 1Y (TTM)6.19%

Revenue growth 3Y1.45%

Revenue growth 5Y1.2%

Sales Q2Q%3.74%

3.2 Future

Based on estimates for the next years, IART will show a small growth in Earnings Per Share. The EPS will grow by 3.38% on average per year.

IART is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.92% yearly.

EPS Next Y-10.77%

EPS Next 2Y-1.06%

EPS Next 3Y3.38%

EPS Next 5YN/A

Revenue Next Year3.34%

Revenue Next 2Y3.88%

Revenue Next 3Y3.92%

Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 5.59, which indicates a rather cheap valuation of IART.

Based on the Price/Earnings ratio, IART is valued cheaper than 97.86% of the companies in the same industry.

When comparing the Price/Earnings ratio of IART to the average of the S&P500 Index (27.28), we can say IART is valued rather cheaply.

The Price/Forward Earnings ratio is 5.40, which indicates a rather cheap valuation of IART.

IART's Price/Forward Earnings ratio is rather cheap when compared to the industry. IART is cheaper than 98.40% of the companies in the same industry.

Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, IART is valued rather cheaply.

		Industry Rank	Sector Rank
PE	5.59
Fwd PE	5.4

4.2 Price Multiples

IART's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IART is cheaper than 95.19% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	8.2

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-1.06%

EPS Next 3Y3.38%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IART does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INTEGRA LIFESCIENCES HOLDING

NASDAQ:IART (7/2/2025, 8:00:02 PM)

After market: 13.52 0 (0%)

13.52

+0.27 (+2.04%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)05-05 2025-05-05/bmo

Earnings (Next)07-23 2025-07-23/bmo

Inst Owners96.59%

Inst Owner Change9.1%

Ins Owners3.32%

Ins Owner Change2.07%

Market Cap1.05B

Analysts54.44

Price Target17.05 (26.11%)

Short Float %9.21%

Short Ratio4.42

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)2.18%

Min EPS beat(2)-6.76%

Max EPS beat(2)11.12%

EPS beat(4)2

Avg EPS beat(4)1.7%

Min EPS beat(4)-6.76%

Max EPS beat(4)11.12%

EPS beat(8)3

Avg EPS beat(8)2.41%

EPS beat(12)5

Avg EPS beat(12)3.04%

EPS beat(16)8

Avg EPS beat(16)4.75%

Revenue beat(2)0

Avg Revenue beat(2)-2.05%

Min Revenue beat(2)-2.51%

Max Revenue beat(2)-1.58%

Revenue beat(4)0

Avg Revenue beat(4)-1.38%

Min Revenue beat(4)-2.51%

Max Revenue beat(4)-0.64%

Revenue beat(8)0

Avg Revenue beat(8)-1.35%

Revenue beat(12)1

Avg Revenue beat(12)-1.19%

Revenue beat(16)3

Avg Revenue beat(16)-0.84%

PT rev (1m)-17.02%

PT rev (3m)-36.33%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-24.6%

EPS NY rev (1m)0.05%

EPS NY rev (3m)-8.97%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-5.27%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-0.87%

Valuation

		Industry Rank	Sector Rank
PE	5.59
Fwd PE	5.4
P/S	0.65
P/FCF	N/A
P/OCF	10.26
P/B	0.69
P/tB	N/A
EV/EBITDA	8.2

EPS(TTM)2.42

EY17.9%

EPS(NY)2.51

Fwd EY18.54%

FCF(TTM)-0.33

FCFYN/A

OCF(TTM)1.32

OCFY9.74%

SpS20.9

BVpS19.61

TBVpS-9.89

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-0.71%
ROE	-1.9%
ROCE	5.36%
ROIC	4.48%
ROICexc	4.91%
ROICexgc	24.71%
OM	10.34%
PM (TTM)	N/A
GM	58.47%
FCFM	N/A

ROA(3y)2.09%

ROA(5y)2.89%

ROE(3y)4.61%

ROE(5y)6.54%

ROIC(3y)6.1%

ROIC(5y)6.15%

ROICexc(3y)6.8%

ROICexc(5y)7%

ROICexgc(3y)25.35%

ROICexgc(5y)25.69%

ROCE(3y)7.3%

ROCE(5y)7.36%

ROICexcg growth 3Y-1.99%

ROICexcg growth 5Y0.59%

ROICexc growth 3Y-12.19%

ROICexc growth 5Y-7.26%

OM growth 3Y-14.31%

OM growth 5Y-7.91%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.19%

GM growth 5Y-1.66%

F-Score5

Asset Turnover0.4

Health

		Industry Rank	Sector Rank
Debt/Equity	0.81
Debt/FCF	N/A
Debt/EBITDA	3.9
Cap/Depr	86.65%
Cap/Sales	7.87%
Interest Coverage	250
Cash Conversion	32.45%
Profit Quality	N/A
Current Ratio	1.21
Quick Ratio	0.72
Altman-Z	1.16

F-Score5

WACC7.4%

ROIC/WACC0.61

Cap/Depr(3y)58.38%

Cap/Depr(5y)54.07%

Cap/Sales(3y)4.82%

Cap/Sales(5y)4.45%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-16.84%

EPS 3Y-6.97%

EPS 5Y-1.35%

EPS Q2Q%-25.45%

EPS Next Y-10.77%

EPS Next 2Y-1.06%

EPS Next 3Y3.38%

EPS Next 5YN/A

Revenue 1Y (TTM)6.19%

Revenue growth 3Y1.45%

Revenue growth 5Y1.2%

Sales Q2Q%3.74%

Revenue Next Year3.34%

Revenue Next 2Y3.88%

Revenue Next 3Y3.92%

Revenue Next 5YN/A

EBIT growth 1Y-33.28%

EBIT growth 3Y-13.07%

EBIT growth 5Y-6.81%

EBIT Next Year16.37%

EBIT Next 3Y9.92%

EBIT Next 5YN/A

FCF growth 1Y-112.75%

FCF growth 3Y-61.56%

FCF growth 5Y-31.13%

OCF growth 1Y-58.45%

OCF growth 3Y-25.46%

OCF growth 5Y-10.98%

INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens